Analysis of vitamin D metabolites in survivors of infantile idiopathic hypercalcemia caused by CYP24A1 mutation or SLC34A1 mutation.

Ewa Kowalska, Rafał Rola, Marek Wójcik, Natalia Łaszcz, Paweł Płudowski, Aldona Wierzbicka, Agnieszka Janiec, Janusz Książyk, Paulina Halat, Elżbieta Ciara, Łukasz Obrycki, Ewa Pronicka, Mieczysław Litwin

Journal: The Journal of steroid biochemistry and molecular biology 2021;208():105824

PMID: 33516786

Abstract

UNLABELLED

Infantile hypercalcemia (IH), is a rare disorder caused by CYP24A1 or SLC34A1 variants which lead to disturbed catabolism of 25(OH)D and 125(OH)D or increased generation of 125(OH)D.

AIM OF STUDY

To assess the status of 2425(OH)D and other markers of vitamin D in IH survivors, in whom variants of CYP24A1 or SLC34A1 gene were found and to compare these unique biochemical features with those obtained from subjects who were diagnosed in the first year of life with hypercalcemia, elevated 25(OH)D and low PTH but in whom neither CYP24A1 nor SLC34A1 variant was found.

PATIENTS AND METHODS

16 IH survivors in whom CYP24A1 (n = 13) or SLC34A1 (n = 3) variants were found and 41 subjects in whom hypercalcemia was diagnosed in the first year of life but in whom CYP24A1 or SLC34A1 variants were not found were included in the study. 25(OH)D, 3-epi-25(OH)D, 25(OH)D, 2425(OH)D were assessed by liquid chromatography coupled with tandem mass spectrometry. 125(OH)D concentrations were assessed by chemiluminescence.

RESULTS

Subjects with CYP24A1 variants, despite normal 25(OH)D levels, had higher 25(OH)D/2425(OH)D ratio values (487; 265-1073 ng/mL) when compared to subjects with SLC34A1 variants (16; 16-23 ng/mL) and with subjects in whom CYP24A1 or SLC34A1 were not found (56; 9-56 ng/mL) (p = 0.00003). Separation of interfering metabolite further increased differences between subjects with and without CYP24A1 mutation.

CONCLUSIONS

Survivors of IH with CYP24A1 variant, despite being normocalcemic, still presented extremely high 25(OH)D/2425(OH)D ratio values. Separation of interfering compound further increased differences between subjects with CYP24A1 mutation and without this mutation.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Address: Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland.; Department of Pediatrics and Nutrition, The Children's Memorial Health Institute, Warsaw, Poland.; Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland.; Department of Nephrology and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.; Department of Nephrology and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland. Electronic address: [email protected].

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.